Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869943 · ClinicalTrials.gov registry record · Phase 3
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
A Phase 3 study, sponsored by Veru.
- Terminated
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT04869943 is a Phase 3 study that was terminated before completion, run by Veru. The registered enrollment target is 52 participants.
The verdict
NCT04869943, a Phase 3 study, was terminated before completion, sponsored by Veru.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).
Interventions
- DRUG Exemestane
- DRUG Enobosarm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-10-12 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04869943
The ClinicalTrials.gov registry entry for NCT04869943 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT04869943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04869943 about?
NCT04869943 is a clinical study titled "Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer". To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).
What is the current status of trial NCT04869943?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2021-10-12. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT04869943?
The interventions under investigation include: Exemestane (DRUG), Enobosarm (DRUG).
Who is sponsoring clinical trial NCT04869943?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.